Danaher Wins Race to Acquire Abcam With $5.7 Billion Deal
- Abcam makes proteins, antibodies for thousands of scientists
- Danaher looking to expand services for life-science industry
Abcam research vials for antibodies.
Photographer: Abcam PlcThis article is for subscribers only.
Danaher Corp. said it will acquire Abcam Plc in a deal worth $5.7 billion, beating out rivals in a race to acquire the UK-based maker of supplies for the life-sciences industry whose technologies are used by thousands of researchers.
Danaher will pay $24 a share for Cambridge, England based Abcam, according to a statement Monday. The transaction, which includes debt and acquired cash, is seen closing in mid-2024, and Danaher expects to fund it using cash and proceeds from issuing commercial paper.